Summary: Deepbridge Life Sciences SEIS
The Deepbridge Life Sciences SEIS is an opportunity to participate in a diversified portfolio of early-stage life science companies, whilst taking advantage of the considerable income tax, capital gains tax, and inheritance tax benefits available under the Seed Enterprise Investment Scheme.
The global Life Sciences industry is one of the leading sources of innovation. Over the past 100 years, life science research has resulted in scores of breakthrough therapies and new methods for the early detection of disease. Major trends, such as the worldwide increase in populations over the age of 60, will drive the future need for an increasing range of new, cost effective health care products for decades to come.
We also offer a Technology SEIS fund, for more details on this click here.
The Deepbridge Life Sciences SEIS seeks to fund companies with exciting new technologies that satisfy the needs of large and growing markets. The overarching focus of the Deepbridge Life Sciences SEIS offers investors companies engaged in the development of therapeutics for the following areas:
- Medical technology including digital healthcare.
There are no management charges levied on the investor at the point of investment for subscriptions received by a financial adviser, resulting in up to 100% allocation of subscription. This ensures up to 100% tax efﬁciency for investors. Deepbridge fees are paid by the Investee Companies and are disclosed in the Information Memorandum.
Please note that for direct investors (i.e. those that subscribe without a financial adviser involved), an additional charge of 2.5% including VAT will be deducted from the subscription to cover Deepbridge's costs associated with verifying the appropriateness of the Deepbridge EIS application.
Performance fee: an incentive fee of 20% of cash returned, in excess of 150% of the funds invested.
For clarification, once the Investor has received in cash the first 150 pence per 100 pence invested (ignoring any tax relief and representing a 20% Hurdle Rate on funds invested), any additional distributable cash will be paid as to 80% to the Investor and 20% to Deepbridge.
Please see the Information Memorandum for full details.